June 4, 2020 / 1:35 PM / a month ago

BRIEF-Abbvie Says Rinvoq's Safety Profile Was Consistent Across Pivotal Phase 3 Program

June 4 (Reuters) - Abbvie Inc:

* NEW LONG-TERM DATA FROM RINVOQ™ (UPADACITINIB, 15 MG) PHASE 3 STUDIES IN RHEUMATOID ARTHRITIS PRESENTED AT 2020 ANNUAL EUROPEAN E-CONGRESS OF RHEUMATOLOGY (EULAR)

* ABBVIE INC - RINVOQ’S SAFETY PROFILE WAS CONSISTENT ACROSS PIVOTAL PHASE 3 PROGRAM, WITH NO NEW SAFETY SIGNALS IDENTIFIED

* ABBVIE INC - RESULTS FROM SELECT-EARLY AND SELECT-COMPARE SHOWED RINVOQ INHIBITED STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS

* ABBVIE - LONG-TERM RESULTS FROM TWO STUDIES SHOWED RINVOQ IMPROVED SIGNS AND SYMPTOMS IN PATIENTS WITH RHEUMATOID ARTHRITIS THROUGH 72 AND 84 WEEKS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below